Strategi Peningkatan Kelarutan Diflunisal: Tinjauan Komprehensif terhadap Pendekatan Formulasi dan Multikomponen Kristal

Bagikan artikel ini Bagikan via WhatsApp

Statistik artikel

Data OJS dan sumber sitasi
Tayangan abstrak0OJS
Unduhan artikel0OJS
Sitasi Crossref—Belum tersedia
Sitasi Google Scholar—Belum terverifikasi

Tayangan dan unduhan adalah aktivitas yang tercatat di OJS; pemrosesan statistik dapat tertunda. Tanda — berarti angka dari sumber tersebut belum tersedia. Cari di Google Scholar

Isi Artikel Utama

Dandi Ananda Putra
Erizal Zaini
Rini Agustin

Abstrak

Diflunisal merupakan obat antiinflamasi nonsteroid (OAINS) yang termasuk dalam Kelas II berdasarkan Sistem Klasifikasi Biofarmasetika (Biopharmaceutics Classification System, BCS), dengan karakteristik permeabilitas tinggi tetapi kelarutan yang rendah dalam air, sehingga membatasi laju disolusi dan bioavailabilitas oralnya. Meskipun berbagai strategi telah dikembangkan untuk mengatasi keterbatasan tersebut, kajian yang secara komprehensif membandingkan pendekatan berbasis formulasi dengan rekayasa kristal multikomponen pada obat model BCS Kelas II yang sama masih terbatas. Kajian naratif ini bertujuan mengevaluasi berbagai strategi peningkatan kelarutan dan disolusi diflunisal berdasarkan sebelas artikel penelitian primer yang diterbitkan pada periode 2010–2025, dengan didukung oleh sejumlah literatur relevan lainnya. Pembahasan difokuskan pada metode preparasi, karakterisasi keadaan padat, serta pengaruh modifikasi formulasi dan struktur kristal terhadap sifat fisikokimia dan biofarmasetika diflunisal. Pendekatan formulasi, meliputi dispersi padat, pengecilan ukuran partikel, dan metode Supercritical Antisolvent (SAS), terbukti mampu meningkatkan disolusi melalui penurunan derajat kristalinitas dan peningkatan luas permukaan. Secara khusus, kristalinitas diflunisal tidak lagi terdeteksi pada kopresipitat diflunisal–PVP yang dipreparasi menggunakan metode SAS. Sementara itu, pendekatan rekayasa kristal, yang mencakup kokristal, garam, kristal obat–obat, dan sistem eutektik, mampu memodifikasi susunan kristal serta interaksi antarmolekul tanpa mengubah struktur kimia diflunisal. Kokristal diflunisal–nikotinamida (2:1) menunjukkan peningkatan laju disolusi intrinsik sekitar 20%, sedangkan kokristal diflunisal–teofilin mampu meningkatkan kelarutan tampak dengan mempertahankan laju disolusi intrinsik yang sebanding dengan diflunisal murni. Secara keseluruhan, pembentukan kokristal menunjukkan potensi yang menjanjikan sebagai strategi peningkatan sifat biofarmasetika diflunisal. Namun, belum tersedianya penelitian yang membandingkan berbagai pendekatan secara langsung serta masih dominannya bukti yang diperoleh melalui pengujian in vitro menjadi keterbatasan utama. Oleh karena itu, penelitian lebih lanjut diperlukan untuk mengevaluasi stabilitas jangka panjang, kelayakan peningkatan skala produksi, serta kinerja in vivo dari sistem yang dikembangkan.

Rincian Artikel

Bagian

Review Article

Cara Mengutip

Strategi Peningkatan Kelarutan Diflunisal: Tinjauan Komprehensif terhadap Pendekatan Formulasi dan Multikomponen Kristal. (2020). Journal of Pharmaceutical and Sciences, 9(4), 3537-3550. https://doi.org/10.36490/journal-jps.com.v9i4.1779

Referensi

[1] Kumar S, Bhargava D, Thakkar A, Arora S. Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review. Crit Rev Ther Drug Carrier Syst. 2013;30(3):217-256. doi:10.1615/CritRevTherDrugCarrierSyst.2013005964.

[2] Rosso C, Birolo R, Gallo A, Franks WT, Priola E, Chierotti MR, et al. Exploring tyramine's role in the formation of supramolecular adducts with nonsteroidal anti-inflammatory drugs. Chem Eur J. 2025;31:e202500080. doi:10.1002/chem.202500080.

[3] Mahmood T, Sarfraz RM, Ismail A, Ali M, Khan AR. Pharmaceutical methods for enhancing the dissolution of poorly water-soluble drugs. Assay Drug Dev Technol. 2023;21(2):65-79. doi:10.1089/adt.2022.119.

[4] Kumari L, Choudhari Y, Patel P, Das Gupta G, Singh D, Rosenholm JM, et al. Advancement in solubilization approaches: a step towards bioavailability enhancement of poorly soluble drugs. Life (Basel). 2023;13(5):1099. doi:10.3390/life13051099.

[5] Cherukuvada S, Bolla G, Nangia A. Crystal engineering of pharmaceutical cocrystals in the discovery and development of improved drugs. Chem Commun (Camb). 2022;58:10050-10065. doi:10.1039/D2CC02917A.

[6] Bhatia M, Devi S. Co-crystallization: a green approach for the solubility enhancement of poorly soluble drugs. CrystEngComm. 2024;26:293-311. doi:10.1039/D3CE01047C.

[7] Wang L, Tan B, Zhang H, Deng Z. Pharmaceutical cocrystals of diflunisal with nicotinamide or isonicotinamide. Org Process Res Dev. 2013;17(11):1413-1418. doi:10.1021/op400182k.

[8] Pallipurath AR, Civati F, Eziashi M, Omar E, McArdle P, Erxleben A. Tailoring cocrystal and salt formation and controlling the crystal habit of diflunisal. Cryst Growth Des. 2016;16(11):6468-6478. doi:10.1021/acs.cgd.6b01154.

[9] Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications. Acta Pharm Sin B. 2021;11(8):2537-2564. doi:10.1016/j.apsb.2021.03.030.

[10] Évora AOL, Castro RAE, Maria TMR, Silva MR, ter Horst JH, Canotilho J, et al. A thermodynamic based approach on the investigation of a diflunisal pharmaceutical co-crystal with improved intrinsic dissolution rate. Int J Pharm. 2014;466(1-2):68-75. doi:10.1016/j.ijpharm.2014.02.048.

[11] Zahran F, Cabañas A, Cheda JAR, Renuncio JAR, Pando C. Dissolution rate enhancement of the anti-inflammatory drug diflunisal by coprecipitation with a biocompatible polymer using carbon dioxide as a supercritical fluid antisolvent. J Supercrit Fluids. 2014;88:56-65. doi:10.1016/j.supflu.2014.01.015.

[12] Cuadra IA, Cabañas A, Cheda JAR, Martínez-Casado FJ, Pando C. Pharmaceutical co-crystals of the anti-inflammatory drug diflunisal and nicotinamide obtained using supercritical CO₂ as an antisolvent. J CO2 Util. 2016;13:29-37. doi:10.1016/j.jcou.2015.11.006.

[13] Évora AOL, Castro RAE, Maria TMR, Rosado MTS, Silva MR, Beja AM, et al. Pyrazinamide-diflunisal: a new dual-drug co-crystal. Cryst Growth Des. 2011;11(11):4780-4788. doi:10.1021/cg200288b.

[14] Wu H, Xue J, Wang Q, Jin S, Zhang Z, Hong Z, et al. Solid phase drug-drug pharmaceutical co-crystal formed between pyrazinamide and diflunisal: structural characterization based on terahertz/Raman spectroscopy combining with DFT calculation. Spectrochim Acta A Mol Biomol Spectrosc. 2020;234:118265. doi:10.1016/j.saa.2020.118265.

[15] Surov AO, Voronin AP, Manin AN, Manin NG, Kuzmina LG, Churakov AV, et al. Pharmaceutical cocrystals of diflunisal and diclofenac with theophylline. Mol Pharm. 2014;11(10):3707-3715. doi:10.1021/mp5004652.

[16] Bhattacharya B, Mondal A, Soni SR, Das S, Bhunia S, Raju KB, et al. Multidrug salt forms of norfloxacin with non-steroidal anti-inflammatory drugs: solubility and membrane permeability studies. CrystEngComm. 2018;20:6420-6429. doi:10.1039/C8CE00900G.

[17] Bag PP, Ghosh S, Khan H, Devarapalli R, Reddy CM. Drug-drug salt forms of ciprofloxacin with diflunisal and indoprofen. CrystEngComm. 2014;16(32):7393-7396. doi:10.1039/C4CE00631C.

[18] Wang Y, Xue J, Wang Q, Jin S, Zhang Z, Hong Z, et al. Structural investigation of a 2:1 co-crystal between diflunisal and isonicotinamide based on terahertz and Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2019;216:98-104. doi:10.1016/j.saa.2019.03.023.

[19] Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5(3):101-117.

[20] Sukhera J. Narrative reviews: flexible, rigorous, and practical. J Grad Med Educ. 2022;14(4):414-417.

[21] Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.

[22] Bolla G, Sarma B, Nangia AK. Crystal engineering of pharmaceutical cocrystals in the discovery and development of improved drugs. Chem Rev. 2022;122(13):11514-11603.

[23] Good DJ, Rodríguez-Hornedo N. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des. 2009;9(5):2252-2264. doi:10.1021/cg801039j.

[24] Kuminek G, Cao F, Bahia de Oliveira da Rocha A, Cardoso SG, Rodríguez-Hornedo N. Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5. Adv Drug Deliv Rev. 2016;101:143-166.

[25] Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453(1):101-125. doi:10.1016/j.ijpharm.2012.10.043.

[26] Cruz-Cabeza AJ. Acid–base crystalline complexes and the pKa rule. CrystEngComm. 2012;14(20):6362-6365.

[27] Cherukuvada S, Nangia A. Eutectics as improved pharmaceutical materials: design, properties and characterization. Chem Commun. 2014;50(8):906-923.

[28] Baghel S, Cathcart H, O’Reilly NJ. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016;105(9):2527-2544.

[29] Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88(10):1058-1066.

[30] Trask AV, Motherwell WDS, Jones W. Physical stability enhancement of theophylline via cocrystallization. Int J Pharm. 2006;320(1-2):114-123.

[31] Karimi-Jafari M, Padrela L, Walker GM, Croker DM. Creating cocrystals: a review of pharmaceutical cocrystal preparation routes and applications. Cryst Growth Des. 2018;18(10):6370-6387.

[32] Douroumis D, Ross SA, Nokhodchi A. Advanced methodologies for cocrystal synthesis. Adv Drug Deliv Rev. 2017;117:178-195.

[33] Padrela L, Rodrigues MA, Duarte A, Dias AMA, Braga MEM, de Sousa HC. Supercritical carbon dioxide-based technologies for the production of drug nanoparticles/nanocrystals – a comprehensive review. Adv Drug Deliv Rev. 2018;131:22-78.

[34] U.S. Food and Drug Administration. Regulatory classification of pharmaceutical co-crystals: guidance for industry, revision 1. Silver Spring (MD): FDA, Center for Drug Evaluation and Research; 2018.

[35] Zhang XR, Zhang XH, Xie XY, Luo JY, Chen HJ, Gao L. Enhancing the solubility and dissolution rate of diflunisal through piperazine stoichiometric variants: reversible transformation and dissolution advantages. J Mol Struct. 2025;1346:143196. doi:10.1016/j.molstruc.2025.143196.

[36] Duggirala NK, Perry ML, Almarsson Ö, Zaworotko MJ. Pharmaceutical cocrystals: along the path to improved medicines. Chem Commun. 2016;52(4):640-655. doi:10.1039/C5CC08216A.

[37] Babu NJ, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des. 2011;11(7):2662-2679.

[38] European Medicines Agency. Reflection paper on the use of cocrystals of active substances in medicinal products. London: EMA; 2015.

Artikel paling banyak dibaca berdasarkan penulis yang sama